| AD-MSCs | adipose tissue-derived mesenchymal stem cells |
| ARD | absolute risk difference |
| BMD | bone mineral density |
| BM-MSC | bone marrow-derived mesenchymal stem cell |
| BMP | bone morphogenetic protein |
| BP | bisphosphonate |
| CI | confidence interval |
| DKK | dickkopf |
| ES | embryonic stem |
| FDA | US Food and Drug Administration |
| iPS | induced pluripotent stem |
| iPSC-MSCs | iPS cell-derived MSCs |
| LRP | lipoprotein receptor-related protein |
| MSCs | mesenchymal stem cells |
| OR | odds ratio |
| OPG | osteoprotegerin |
| PTH | parathyroid hormone |
| RCT | randomized controlled trial |
| RR | relative risk |
| Runx2 | runt-related transcription factor 2 |
| RANKL | receptor activator of nuclear factor κB ligand |
| SERM | selective estrogen receptor modulator |
| siRNA | small interfering RNA |
| WMD | weighted mean differences |